Detalhe da pesquisa
1.
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Clin Infect Dis
; 76(3): e1177-e1185, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36164254
2.
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
J Antimicrob Chemother
; 78(11): 2702-2714, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726401
3.
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
J Antimicrob Chemother
; 72(11): 3131-3140, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961737
4.
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
PLoS Negl Trop Dis
; 10(9): e0004880, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27627654
5.
Validation of two rapid diagnostic tests for visceral leishmaniasis in Kenya.
PLoS Negl Trop Dis
; 7(9): e2441, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24086782